SPI Infoamtion

Table of Contents

1. Executive Summary

2. Dyslipidemia and Coronary Heart Disease
2.1 Cholesterol and Triglycerides
2.2 Lipoproteins Transport Cholesterol and Triglycerides
2.3 Dyslipidemia and Atherosclerosis
2.4 Cholesterol Risk Levels
2.5 The Fredrickson/World Health Organization (WHO) Classification of Dyslipidemia
2.6 Cardiovascular Disease
2.7 CHD Risk Factors
2.8 Cholesterol Testing
2.9 Primary and Secondary Prevention of Atherosclerosis

3. Statins and Other Lipid-Lowering Drugs
3.1 Statins: Mechanism of Action and Types
3.2 Lovastatin
3.2.1 Lovastatin Indications
3.2.2 Lovastatin Brands and Generic Manufacturers
3.3 Simvastatin
3.3.1 Simvastatin Indications
3.4 Pravastatin
3.4.1 Pravastatin Indications
3.4.2 Pravastatin Brands and Generic Manufacturers
3.5 Fluvastatin
3.5.1 Fluvastatin Indications
3.5.2 Fluvastatin Brands and Generic Manufacturers
3.6 Atorvastatin
3.6.1 Atorvastatin Indications
3.6.2 Atorvastatin Brands and Generic Manufacturers
3.7 Rosuvastatin
3.7.1 Rosuvastatin Indications
3.7.2 Rosuvastatin Brands and Generic Manufacturers
3.8 Pitavastatin
3.9 Statin/Other Lipid-Lowering Drug Combinations
3.9.1 Lovastatin/Nicotinic Acid
3.9.2 Simvastatin/Nicotinic Acid
3.9.3 Simvastatin/Ezetimibe
3.9.4 Atorvastatin/Fenofibrate
3.9.5 Atorvastatin/Ezetimibe
3.9.6 Atorvastatin/Ezetimibe/Fenofibrate
3.10 Statin/Other Cardiovascular Drug Combinations
3.10.1 Caduet (Atorvastatin/Amlodipine)
3.10.2 Pravadual (Pravastatin/Aspirin)
3.10.3 Generic Statin/Other Cardiovascular Drugs
3.11 Other Dyslipidemia Drugs
3.11.1 Anion-Exchange Resins
3.11.2 Ezetimibe
3.11.3 Fibrates
3.11.4 Nicotinic Acid
3.11.5 Omega-3-Acid Ethyl Esters

4. The World Statins Market 2010-2025
4.1 Statins Dominate the Lipid-Regulating Drug Market
4.1.1 The World Lipid-Regulating Drug Market, 2009
4.1.2 World Lipid-Lowering Drug Market Sales Forecast, 2010-2025
4.2 The World Statin Market
4.2.1 The World Statin Market, 2009
4.2.2 World Statin Market Sales Forecast, 2010-2011
4.2.3 The Impact of Generic Atorvastatin on the World Statin Market, 2011-2014
4.2.4 World Statin Market Sales Forecast, 2015-2020
4.2.5 Prospects for the World Statin Market, 2020-2025
4.2.6 Statin Type Market Sales Forecast, 2010-2025
4.3 The Branded and Generic Statin Markets
4.3.1 The Branded and Generic Statin Markets, 2009
4.3.2 By 2019 Sales of Generic Statins Will Exceed Branded Revenues

5. Leading Statin Types and Products, 2010-2025
5.1 Atorvastatin
5.1.1 The Atorvastatin Market in 2009
5.1.2 Atorvastatin Market Sales Forecast, 2010-2025
5.1.3 Lipitor/Prevencor/Totalip Market Sales Forecast, 2010-2011
5.1.4 Lipitor/Prevencor/Totalip Market Sales Forecast, 2011-2015 - The Ultimate Patent Cliff?
5.1.5 Lipitor/Prevencor/Totalip Market Sales Forecast, 2015-2025
5.1.6 Generic Atorvastatin Market Sales Forecast, 2010-2025
5.2 Rosuvastatin
5.2.1 The Rosuvastatin Market in 2009
5.2.2 Rosuvastatin Market Sales Forecast, 2009-2024
5.2.3 Crestor Market Sales Forecast, 2010-2015
5.2.4 Crestor Market Sales Forecast, 2015-2025
5.2.5 Generic Rosuvastatin Market Sales Forecast, 2010-2025
5.3 Simvastatin
5.3.1 The Simvastatin Market in 2009
5.3.2 Simvastatin Market Sales Forecast, 2010-2025
5.3.3 Zocor Market Sales Forecast, 2010-2025
5.3.4 Generic Simvastatin Market Sales Forecast, 2010-2025
5.4 Pravastatin
5.4.1 The Pravastatin Market in 2009
5.4.2 Pravastatin Market Sales Forecast, 2010-2025
5.4.3 Mevalotin/Pravachol Market Sales Forecast, 2010-2025
5.4.4 Generic Pravastatin Market Sales Forecast, 2010-2025
5.5 Fluvastatin
5.5.1 The Fluvastatin Market in 2009
5.5.2 Fluvastatin Market Sales Forecast, 2010-2025
5.5.3 Lescol Market Sales Forecast, 2010-2025
5.5.4 Generic Fluvastatin Market Sales Forecast, 2010-2025
5.6 Pitavastatin
5.6.1 The Pitavastatin Market in 2009
5.6.2 Pitavastatin Market Sales Forecast, 2010-2025
5.7 Lovastatin
5.7.1 The Lovastatin Market in 2009
5.7.2 Lovastatin Market Sales Forecast, 2010-2025
5.8 Statin/Non-Statin Combination Drugs
5.8.1 The Statin/Non-Statin Combination Drug Market in 2009
5.8.2 Statin/Non-Statin Combination Drugs, 2010-2015
5.8.3 Statin/Non-Statin Combination Drugs, 2015-2025
5.8.4 Vytorin Market Sales Forecast, 2010-2025
5.8.5 Caduet Market Sales Forecast, 2010-2025

6. Leading Statin Manufacturers, 2010
6.1 Five Players Controlled 85% of the Statin Market in 2009
6.2 Pfizer's Statin Revenues Sales Forecast, 2010-2015
6.3 A New Leading Statin Manufacturer by 2013
6.4 Merck & Co Statin Revenues Sales Forecast, 2010-2015

7. Issues Affecting the Statin Industry
7.1 SWOT Analysis of the Statin Industry
7.2 Patient Compliance
7.2.1 Patients on Statins Exhibit Poor Patient Compliance
7.2.2 Effective Contact between Patients and Healthcare Practitioners is the Key to Improving Patient Compliance
7.2.3 Developments in Cholesterol Testing
7.2.4 Diagnostic Testing for Genetic Markers May Increase Patient Compliance
7.2.5 Increasing Use of Web-Based Information Technology Will Improve Patient Compliance
7.3 Generic Statins
7.3.1 Expected Patent Expiries in the Statin Market
7.3.2 Governments and Insurers Will Favour Generic Statins
7.4 Statin Clinical Trials
7.5 Safety of Statins
7.6 Statin OTC Switching
7.6.1 The Rationale for OTC Switching
7.6.2 Statin OTC Switching in the UK
7.6.3 Statin OTC Switching in the US
7.6.4 What are the Worldwide Prospects for Statin OTC Switching?
7.7 Prevalence of Coronary Heart Disease
7.7.1 Coronary Heart Disease is the Leading Cause of Death Worldwide
7.7.2 Future Projections for Prevalence of Coronary Heart Disease
7.7.3 The Economic Cost of Coronary Heart Disease
7.8 Promising Non-Statin Lipid-Lowering Pipeline
7.8.1 Statins Cannot Treat All Forms of Dyslipidemia
7.8.2 Developments in Existing Rivals for Statins
7.8.2.1 Novel Nicotinic Acid Formulations
7.8.2.2 New Formulation of Fibrates
7.8.2.3 Omega-3 Fatty Acids
7.8.2.4 Functional Foods and Nutritional Supplements
7.8.3 Novel Lipid-Lowering Agents
7.8.3.1 CETP Inhibitors
7.8.3.2 Cholesterol Absorption Inhibitors
7.8.3.3 Antisense Oligonucleotides
7.8.3.4 PPAR-Alpha Agonists
7.8.3.5 MTP Inhibitors
7.8.3.6 Phospholipase A2 Inhibitors
7.8.3.7 Nicotinic Acid Receptor Agonists
7.8.3.8 Human Antibodies

8. Interviews with Relevant Experts
8.1 Humayun J. Chaudhry, D.O., M.S., FACP, Commissioner of Health Services, Suffolk County, New York
8.1.1 Improving Patient Compliance in Statin Therapy
8.1.2 The Future of Cholesterol Testing
8.1.3 Web-Based Information Technology in Statin Prescribing
8.2 Amir Shroufi, PhD, Cambridge Institute of Public Health
8.2.1 The Importance of Improving Patient Adherence (Compliance) in Statin Therapy
8.2.2 Methods of Improving Patient Adherence
8.2.3 Limitations of Using Statins to Lower Cholesterol
8.2.4 Unmet Needs
8.2.5 Challenges for Research into Patient Adherence

9. Statin Country Markets, 2010-2025
9.1 Leading Country Markets in 2009
9.2 Leading Country-Market Sales Forecasts, 2010-2025
9.3 The US Statin Market
9.3.1 The US Statin Market in 2009
9.3.2 US Statin Market Sales Forecast, 2010-2015
9.3.3 US Statin Market Sales Forecast, 2015-2025
9.4 The Japanese Statin Market
9.4.1 The Japanese Statin Market in 2009
9.4.2 Japanese Statin Market Sales Forecast, 2010-2025
9.5 The Canadian Statin Market
9.6 European Statin Markets, 2010-2025
9.7 Emerging Statin Markets: China and India

10. The Statin R&D Pipeline
10.1 The Statin Pipeline Lacks Enough New Drug Candidates
10.2 New Statins and Statin Combination Drugs in Development
10.2.1 Crestor/TriLipix
10.2.2 Simvastatin and Nicotinic Acid and Laropiprant
10.2.3 Pravastatin and Fenofibrate Combination Therapy
10.2.4 Simvastatin and Fenofibrate Combination Therapy
10.2.5 Simvastatin/Rosiglitazone
10.2.6 PPD Statin/RBx 10558
10.2.7 NCX 6560

11. Conclusions
11.1 The Statin Market in 2009
11.2 Future Challenges for the Statin Industry
11.3 World Statin Market Sales Forecast, 2010-2025
11.4 Prospects for Leading Statin Manufacturers and Country Markets

List of Tables
Table 2.1 Risk Levels for Total Cholesterol
Table 2.2 Risk Levels for LDL Cholesterol
Table 2.3 Risk Levels for HDL Cholesterol
Table 2.4 Risk Levels for Triglycerides
Table 2.5 The Fredrickson/WHO Classification of Dyslipidemia
Table 3.1 Leading Generic Lovastatin Manufacturers, 2009
Table 3.2 Leading Generic Simvastatin Manufacturers, 2009
Table 3.3 Leading Generic Pravastatin Manufacturers, 2009
Table 3.4 Branded Fibrates, 2009
Table 3.5 Leading Prescription Omega-3 Acid Products, 2009
Table 4.1 World Lipid-Lowering Drug Market, 2009
Table 4.2 World Lipid-Lowering Drug Market Sales Forecasts, 2010-2016
Table 4.3 World Lipid-Lowering Drug Market Sales Forecasts, 2017-2025
Table 4.4 Leading Statin Types and Brands: Sales and Market Shares, 2009
Table 4.5 Statin Drugs: Market Sales Forecasts, 2010-2016
Table 4.6 Statin Drugs: Market Sales Forecasts, 2017-2025
Table 4.7 The Branded and Generic Statin Markets: Sales and Market Shares, 2009
Table 4.8 Branded and Generic Statin Market Sales Forecasts, 2010-2016
Table 4.9 Branded and Generic Statin Market Sales Forecasts, 2017-2025
Table 5.1 Atorvastatin Market: Sales and Market Shares, 2009
Table 5.2 Atorvastatin Drug Sales Forecasts, 2010-2016
Table 5.3 Atorvastatin Drug Sales Forecasts, 2017-2025
Table 5.4 Rosuvastatin: Sales and Market Shares, 2009
Table 5.5 Rosuvastatin Drug Sales Forecasts, 2010-2016
Table 5.6 Rosuvastatin Drug: Sales Forecasts, 2017-2025
Table 5.7 Smivastatin Market: Sales and Market Shares, 2009
Table 5.8 Simvastatin Drug Sales Forecasts, 2010-2016
Table 5.9 Simvastatin Drug Sales Forecasts, 2017-2025
Table 5.10 Pravastatin Market: Sales and Market Shares, 2009
Table 5.11 Pravastatin Drug Sales Forecasts, 2010-2016
Table 5.12 Pravastatin Drug Sales Forecasts, 2017-2025
Table 5.13 Fluvastatin Drug Sales Forecasts, 2010-2016
Table 5.14 Fluvastatin Drug Sales Forecasts, 2017-2025
Table 5.15 Pitavastin Sales Forecast, 2010-2016
Table 5.16 Pitavastin Sales Forecast, 2017-2025
Table 5.17 Lovastatin Sales Forecast, 2010-2016
Table 5.18 Lovastatin Sales Forecast, 2017-2025
Table 5.19 Statin and Statin/Non-Statin Combination Drugs: Sales and Market Shares, 2009
Table 5.20 Statin/Non-Statin Combination Drug: Sales and Market Shares, 2009
Table 5.21 Statin/Non-Statin Combination Drug Sales Forecasts, 2010-2016
Table 5.22 Statin/Non-Statin Combination Drug Sales Forecasts, 2017-2025
Table 6.1 Leading Statin Manufacturers: Sales and Market Shares, 2009
Table 6.2 Leading Statin Manufacturers: Revenue Sales Forecasts, 2010-2015
Table 7.1 SWOT Chart for the Statins Industry, 2010-2025
Table 7.2 Expected Statin Patent Expiry Dates, 2010-2025
Table 9.1 Leading Statin Country Markets: Sales and Market Shares, 2009
Table 9.2 Leading Statin Country-Market Sales Forecasts, 2010-2016
Table 9.3 Leading Statin Country-Market Sales Forecasts, 2017-2025
Table 10.1 The Statin R&D Pipeline, 2009

List of Figures
Figure 4.1 World Lipid Lowering Drug Market Sales Forecast, 2010-2025
Figure 4.2 Statin Type Market Shares, 2009
Figure 4.3 Leading Statin Brands: Market Shares, 2009
Figure 4.4 World Statin Market Sales Forecast, 2010-2025
Figure 4.5 Statin Type Market Sales Forecast, 2010-2025
Figure 4.6 Statin Type Market Shares, 2015
Figure 4.7 Statin Type Market Shares, 2020
Figure 4.8 Statin Type Market Shares, 2025
Figure 4.9 Branded and Generic Statin Market Sales Forecasts, 2010-2025
Figure 5.1 Atorvastatin Drugs: Market Sales Forecasts, 2010-2025
Figure 5.2 Rosuvastatin Drugs: Market Sales Forecasts, 2010-2025
Figure 5.3 Simvastatin Drugs: Market Sales Forecasts, 2010-2025
Figure 5.4 Pravastatin Drugs: Market Sales Forecasts, 2010-2025
Figure 5.5 Fluvastatin Drugs: Market Sales Forecasts, 2010-2025
Figure 5.6 Pitavastin Market Sales Forecast, 2010-2025
Figure 5.7 Lovastatin Market Sales Forecast, 2010-2025
Figure 5.8 Statin Combination Drug Sales Forecasts, 2010-2025
Figure 6.1 Leading Statin Manufacturers: Market Shares, 2009
Figure 6.2 Leading Statin Manufacturers: Revenue Sales Forecasts, 2010-2015
Figure 9.1 Statin Market Shares by Country, 2009
Figure 9.2 Statin Market Shares by Country, 2015
Figure 9.3 Statin Market Shares by Country, 2020
Figure 9.4 Statin Market Shares by Country, 2025
Figure 9.5 US Statin Market Sales Forecast, 2010-2025
Figure 9.6 Japanese, European and Canadian Statin Market Sales Forecasts, 2010-2025
Figure 9.7 China & India Statin Market Sales Forecasts, 2010-2025